A Phase 2 interventional study of statin + ezetimibe and Statin monotherapy (rosuvastatin or atorvastatin) in Ischemic Stroke and Hypercholesteremia, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing statins in Ischemic Stroke — 10 open to participants now, 10 under way, 3 of them phase 3. A drug class: Statins · Ischemic Stroke.
Among the 21 studies testing statins in Ischemic Stroke, this one is the 14th largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 2, and was the 20th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →10 of the 21 studies testing statins in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
Duan Chuanzhi · Sites in China
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 8 · Phase 4 9
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 354 across the 21 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 21 has an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
11 studies in Ischemic Stroke by Chang Gung Memorial Hospital: 2 open now, 3 under way, none of them phase 3. Of 4 finished, 0 (0%) have results posted.
Among the 11 studies in Ischemic Stroke by Chang Gung Memorial Hospital, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 2, and was the 11th registered.
Chang Gung Memorial Hospital’s Ischemic Stroke studies by the year they started, since 2007.
2 of the studies testing statins in Ischemic Stroke that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908875Phase 3First Affiliated Hospital of Wannan Medical CollegeUpfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. | 2027-09-30 |
| NCT05589454Sichuan Provincial People's HospitalIntracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing statins in Ischemic Stroke, from their registry updates:
Among Chang Gung Memorial Hospital’s 11 in Ischemic Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted at six medical institutions in Taiwan, recruiting patients who visit neurology outpatient clinics or are hospitalized within 30 days after an ischemic stroke.
Participants will be randomly assigned to either the experimental group (moderate-intensity statin plus ezetimibe) or the control group (moderate- or high-intensity statin).
Research assistants will screen patients aged 40 or older who have had an ischemic stroke or transient ischemic attack within 30 days, have atherosclerosis, and have LDL-C levels ≥100 mg/dL. Eligible cases will be reviewed by the attending physician. With physician approval, patients will be invited to join the study, and those who agree and sign informed consent will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moderate-intensity statin plus ezetimibe as the interventional group. Both fixed-dose combination of statin/ezetimibe, such as Vytorin (simvastatin 20mg/ezetimibe 10mg), Atozet (atorvastatin 20mg/ezetimibe 10mg), Cretrol (rosuvastatin 10mg/ezetimibe 10mg) and one pill of ezetimibe added to moderate-intensity statins are allowed.
Drug: statin + ezetimibe
Moderate- or high-intensity statin monotherapy, including atorvastatin 10-80 mg/d, rosuvastatin 5-20 mg/d, pitavastatin 1-4 mg/d
Drug: Statin monotherapy (rosuvastatin or atorvastatin)
Drug pages: StatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EzetimibeStudies of EzetimibeEzetimibe pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Moderate-intensity statin plus ezetimibe 10mg
Moderate- or high-intensity statin monotherapy
LDL-C levels < 70 mg/dL
Time frame: 6 months after randomization
LDL-C levels < 70 mg/dL
Time frame: 3 months
Plan to share: No — IRB did not approve sharing data.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2029, 47 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 47 months is above that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Statins · Ezetimibe
Chang Gung Memorial Hospital →